Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATR04-484 for EGFRi-Associated Dermal Toxicity
NCT06830863Phase 2Recruiting
- Sponsor
- Azitra, Inc.
- Start
- Aug 2025
- Primary completion
- Jul 2027
- Modality
- Fecal Microbiota Transplantation (FMT), Live Biotherapeutic Products, Engineered Microbial Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of ATR04-484, sponsored by Azitra, Inc.. Started Aug 2025; status: recruiting.
02
Drugs
ATR04-484
Beyond the preview
Go deeper on NCT06830863.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06830863.